Regeneron tore its manufacturing processes and supply chain apart in an investigation after a spike in a rare side effect was discovered with some patients taking its top-selling sight drug Eylea. While the company says it has found no issues with the drug or its manufacturing, it has found an association between the problem and some Becton Dickinson syringes that were distributed in the U.S.Original Article
You may also like
Pharmaceutical Sales Customer Engagement –...
AstraZeneca’s Polyneuropathy Treatment Recommended...
Designing a Strategic Roadmap for Seamless Product...
AAPS PharmSci 360: LBFs and Tackling Oral Biologic...
CHMP Gives Positive Opinion to Novo Nordisk Hemophilia...
GSK, Cambridge to Partner on R&D for Kidney and...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.